Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 338 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Comparative Effectiveness Study Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: semaglutide, oral glucose-lowering medications (commercially available); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more

Conditions: Pruritis
Interventions: Sarna, Cetaphil; Drug
Lead sponsor: Wake Forest University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Candidiasis
Interventions: Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of Care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Contraception, Change in Bone Mineral Density
Interventions: Drospirenone; Drug
Lead sponsor: Insud Pharma; Industry
Eligibility: 13 Years to 45 Years · Female only
Enrollment: 1,542 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 46
States / cities: Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 36 more

Conditions: Polycystic Ovary
Interventions: DASH diet, Very low-carbohydrate diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: PTSD
Interventions: Cognitive Processing Therapy, STAIR Narrative Therapy; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Palo Alto, California • San Francisco, California

Conditions: Quality of Life, Body Mass Index
Interventions: MannaBears, AlgaeCal Calcium, Calcium carbonate, Vitamin D3; Dietary Supplement
Lead sponsor: Integrative Health Technologies, Inc.; Network
Eligibility: 5 Years to 19 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Plaque Psoriasis
Interventions: Adalimumab, ABP 501; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 35
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 30 more

Conditions: Cardiac Rehabilitation
Interventions: Tailored cardiac rehabilitation, Referral to an external cardiac rehabilitation program; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pediculosis Capitis
Interventions: Licefreee Spray, 1% permethrin creme rinse; Drug
Lead sponsor: South Florida Family Health and Research Centers; Network
Eligibility: 4 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Plantation, Florida

Conditions: Pediatric End Stage Renal Disease, Hemodialysis
Interventions: Hemodialysis; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Pancreatitis
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Surgical Site Infections
Interventions: Iodine-alcohol, Chlorhexidine-alcohol; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: Female only
Enrollment: 1,147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Pectus Excavatum, Pain, Postoperative
Interventions: Multimodal Erector spinae catheter protocol; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 8 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Prostatic Neoplasms
Interventions: CP-751,871, docetaxel, prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • New York, New York • Cleveland, Ohio + 2 more

Conditions: Febrile Neutropenia
Interventions: Daptomycin, Saline Placebo; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Cerebral Palsy
Interventions: Not listed
Lead sponsor: Holland Bloorview Kids Rehabilitation Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 9
States / cities: Sacramento, California • Aurora, Colorado • Wilmington, Delaware + 5 more

Conditions: Healthy Men Age 50 Who Are Considering PSA Screening
Interventions: DESI for home viewing, DESI for viewing at Shared Medical Appointment, Option of SMA and DESI or DESI only; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 2,521 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Palo Alto, California • Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Amlodipine, Chlorthalidone, Losartan; Drug
Lead sponsor: Anthony J Viera, MD, MPH; Other
Eligibility: 30 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Postoperative Pain
Interventions: Bupivacaine HCl, SKY0402; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Birmingham, Alabama • Davis, California • Laguna Hills, California + 3 more

Conditions: Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia, Kidney Disease, End Stage Renal Failure on Dialysis
Interventions: Cardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention, Lifestyle, Medication; Procedure · Behavioral · Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Complicated Skin and Soft Tissue Infection
Interventions: Ceftaroline fosamil, Vancomycin, Aztreonam; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 10
States / cities: Chula Vista, California • Orlando, Florida • West Palm Beach, Florida + 7 more

Conditions: Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions: edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 8,292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 82
States / cities: Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more

Search by objective public record fields.

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females

The Supporting Understanding of PCOS Education and Research (SUPER) Study

A Comparative Effectiveness Study of PTSD Treatments Among Sexual and Gender Minority Populations

Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program

A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis

The Heart Health After Cardiac Treatment Study

Efficacy and Safety of Licefreee Spray Against Nix 1% Permethrin

More Frequent In-Center Hemodialysis in Pediatric End Stage Renal Disease

Idiopathic Recurrent Acute Pancreatitis (IRAP)

The Skin Prep Study

Pectus ESC Outcomes and Comparative Effectiveness Study

Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)

Daptomycin Versus Placebo in Patients With Neutropenia and Fever

Cerebral Palsy Hip Outcomes Project - International Multi-centre Study

Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1

Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study

Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

ISCHEMIA-Chronic Kidney Disease Trial

Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).